<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014101</url>
  </required_header>
  <id_info>
    <org_study_id>ZSGW-PD-1210</org_study_id>
    <nct_id>NCT04014101</nct_id>
  </id_info>
  <brief_title>SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma</brief_title>
  <acronym>SHR-1210</acronym>
  <official_title>A Single Arm Pilot Study of Programmed Cell Death Protein 1 Antibody (PD-1# SHR-1210 Combined With Apatinib Mesylate in Patients With Advanced-Stage Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an
      open- label#single center #non-randomized #Single Arm Exploratory Study . This clinical study
      is an investigator-initiated clinical trial(IIT) .The objective of this study is to evaluate
      the efficacy and safety of therapy with anti-PD-1 antibody SHR-1210 and apatinib in patients
      with advanced stage hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To the relief time (TOR)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of relief(DOR)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-month survival rate</measure>
    <time_frame>9-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month survival rate</measure>
    <time_frame>12-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>SHR-1210+ apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1210 was administered intravenously (without prophylaxis) at a fixed dose of 200 mg for 3 mg/kg for subjects with a baseline weight &lt;50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 2 years; Apatinib was taken orally after meals, once a day, for continuous medication, and 1 cycle every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210</intervention_name>
    <description>SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody</description>
    <arm_group_label>SHR-1210+ apatinib</arm_group_label>
    <other_name>Anti-PD-1 Antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apatinib</intervention_name>
    <description>Apatinib is a selective VEGFR2 inhibitor.</description>
    <arm_group_label>SHR-1210+ apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.≥18 years old, male or female 2.Advanced liver cancer (cannot be removed or
             metastasized) diagnosed clinically or pathologically, at least one measurable lesion
             without local treatment, Child-Pugh A ;Barcelona Clinic Liver Cancer(BCLC) staging is
             stage B or C 3.Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
             4.Patient has given written informed consent. 5.Previous treatment failure with
             sorafenib or rivastatin (disease of disease or toxicity) or unwillingness to accept,
             economically unsustainable sorafenib treatment; 6.The function of important organs
             meets the requirements 7.Expected survival ≥12 weeks 8.Non-surgical sterilization or
             women of childbearing age need to use a medically-accepted contraceptive (such as an
             intrauterine device, contraceptive or condom) during the study period and within 3
             months after the end of the study treatment period; non-surgical sterilization Female
             patients of childbearing age must have a negative serum or urine human chorionic
             gonadotropin(HCG) test within 72 hours prior to study enrollment; and must be
             non-lactating; for male patients with maternal age, they should be given SHR-1210
             during the trial and after the last 3 effective methods of contraception within a
             month.

        Exclusion Criteria:

        - 1.The patient has any active autoimmune disease or a history of autoimmune disease (such
        as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia,
        uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, thyroid
        Hyperfunction; patients with vitiligo; complete remission of asthma in childhood, can be
        included without any intervention after adulthood; asthma patients who require
        bronchodilators for medical intervention cannot be included); 2.The patient is using
        immunosuppressive agents or systemic hormonal therapy to achieve immunosuppressive purposes
        (agents amount &gt; 10 mg / day of prednisone or other therapeutic hormones), and continue to
        use within 2 weeks before enrollment; 3.Have clinical symptoms or disease that are not well
        controlled 4.Significant clinically significant bleeding symptoms or a clear bleeding
        tendency within 3 months prior to randomization 5.Arterial/venous thrombosis in the first 6
        months of randomization 6.According to the investigator, the patient has other factors that
        may affect the results of the study or lead to the termination of the study, such as
        alcohol abuse, drug abuse, other serious diseases (including mental illness) requiring
        combined treatment, and serious laboratory abnormalities.，with family or social factors, it
        will affect the safety of patients.

        7.Liver tumor burden greater than 50% of the total liver volume, or patients who have
        previously undergone liver transplantation;Known for a history of central nervous system
        metastasis or hepatic encephalopathy;Severe allergic reactions to other monoclonal
        antibodies;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia Fan, PHD</last_name>
    <phone>021 64041990/680774</phone>
    <email>:fan.jia@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>: Jia Fan, PHD</last_name>
      <phone>021 64041990/680774</phone>
      <email>fan.jia@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

